• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Human factor IX inhibitors: immunochemical characteristics and treatment with activated concentrate.

作者信息

Giddings J C, Bloom A L, Kelly M A, Spratt H C

出版信息

Clin Lab Haematol. 1983;5(2):165-75. doi: 10.1111/j.1365-2257.1983.tb01349.x.

DOI:10.1111/j.1365-2257.1983.tb01349.x
PMID:6603957
Abstract

Plasma was obtained from two patients with severe factor IX deficiency who had developed specific inhibitors of factor IX. Immunochemical characterization of the inhibitors by coagulation inhibitor neutralization assays and by immunoelectrophoretic methods demonstrated that both were IgG antibodies. One of the antibodies appeared to be monoclonal in origin with IgG subclass 4 heavy chains and lambda light chains. The other appeared to be oligoclonal and contained IgG subclass 1 and subclass 4 heavy chains and kappa and lambda light chains. One of the patients was treated with conventional, non-activated factor IX concentrate and with activated factor IX concentrate (Feiba) for repeated bleeding episodes. Administration of Feiba resulted in a progressive shortening of the kaolin cephalin clotting time and was followed by a good clinical response. Infusion of non-activated factor IX concentrate failed to induce clinical resolution of haemarthroses and had minimal effect on laboratory tests. The presence of circulating immune complexes could not be demonstrated in this patient.

摘要

相似文献

1
Human factor IX inhibitors: immunochemical characteristics and treatment with activated concentrate.
Clin Lab Haematol. 1983;5(2):165-75. doi: 10.1111/j.1365-2257.1983.tb01349.x.
2
Characterization of an occult inhibitor to factor IX in a haemophilia B patient.一名B型血友病患者中IX因子隐匿性抑制剂的特征分析
Br J Haematol. 1985 Oct;61(2):329-38. doi: 10.1111/j.1365-2141.1985.tb02833.x.
3
Alloantibodies to factor IX in Haemophilia B characterized by crossed immunoelectrophoresis and enzyme-conjugated antisera to human immunoglobulins.通过交叉免疫电泳和酶联抗人免疫球蛋白血清对B型血友病中因子IX的同种抗体进行鉴定。
Br J Haematol. 1981 May;48(1):15-23.
4
IgG subclass identification of inhibitors to factor IX in haemophilia B patients.
Br J Haematol. 1988 Apr;68(4):451-4. doi: 10.1111/j.1365-2141.1988.tb04234.x.
5
Factor IX alloantibodies shorten the bovine thromboplastin coagulation time of normal human plasma.因子IX同种抗体可缩短正常人血浆的牛凝血酶原时间。
Thromb Haemost. 1981 Dec 23;46(4):684-6.
6
Inhibitor antibodies to factor VIII and factor IX: management.针对凝血因子VIII和凝血因子IX的抑制性抗体:管理
Semin Thromb Hemost. 2000;26(2):179-88. doi: 10.1055/s-2000-9821.
7
Spontaneous disappearance of an IgA anti-factor IX inhibitor in a child with Christmas disease.一名患有克里斯马斯病的儿童体内IgA抗因子IX抑制剂的自发消失
Am J Hematol. 1984 Oct;17(3):321-5. doi: 10.1002/ajh.2830170312.
8
A novel therapeutic approach combining human plasma-derived Factors VIIa and X for haemophiliacs with inhibitors: evidence of a higher thrombin generation rate in vitro and more sustained haemostatic activity in vivo than obtained with Factor VIIa alone.一种将人血浆源性凝血因子VIIa和X联合用于有抑制剂的血友病患者的新型治疗方法:体外凝血酶生成率更高以及体内止血活性比单独使用凝血因子VIIa更持久的证据。
Vox Sang. 2003 Nov;85(4):290-9. doi: 10.1111/j.0042-9007.2003.00365.x.
9
Analysis of IgG heavy chain subclasses of alloantibodies to factor IX by crossed immunoelectrophoresis of factor IX using the intermediate gel technique.采用中间凝胶技术,通过因子IX的交叉免疫电泳分析针对因子IX的同种抗体的IgG重链亚类。
Br J Haematol. 1983 Apr;53(4):687-8. doi: 10.1111/j.1365-2141.1983.tb07323.x.
10
Risk and prevention of anti-factor IX formation in AAV-mediated gene transfer in the context of a large deletion of F9.在F9基因大片段缺失情况下,腺相关病毒介导的基因转移中抗因子IX形成的风险与预防
Mol Ther. 2001 Sep;4(3):201-10. doi: 10.1006/mthe.2001.0441.

引用本文的文献

1
Survey of the anti-factor IX immunoglobulin profiles in patients with hemophilia B using a fluorescence-based immunoassay.使用基于荧光的免疫测定法对乙型血友病患者的抗因子IX免疫球蛋白谱进行调查。
J Thromb Haemost. 2016 Oct;14(10):1931-1940. doi: 10.1111/jth.13438. Epub 2016 Sep 17.
2
Induction of split tolerance and clinical cure in high-responding hemophiliacs with factor IX antibodies.诱导高反应性血友病患者产生分裂耐受性并实现临床治愈,这些患者体内存在因子IX抗体。
Proc Natl Acad Sci U S A. 1986 Dec;83(23):9169-73. doi: 10.1073/pnas.83.23.9169.